Biotechnology company Shattuck Labs Inc. (STTK) is advancing innovative therapies for autoimmune and inflammatory diseases, led by SL 325, a potential first-in-class antibody targeting the DR3/TL1A pathway. With a pipeline of bispecific antibodies in development and financing that extends its cash runway into 2029, the company combines scientific progress with long-term stability. These factors, along with recent market momentum, make STTK a name to keep on the radar.
A Signal in the Market
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com